Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1

PURPOSE: Because dexamethasone remains a key component of myeloma therapy, we wished to examine the impact of baseline and relapse expression levels of the glucocorticoid receptor gene NR3C1 on survival outcomes in the context of treatment with or without thalidomide. EXPERIMENTAL DESIGN: We investi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Heuck, Christoph J, Szymonifka, Jackie, Hansen, Emily, Shaughnessy, John D., Usmani, Saad Z, van Rhee, Frits, Anaissie, Elias, Nair, Bijay, Waheed, Sarah, Alsayed, Yazan, Petty, Nathan, Bailey, Clyde, Epstein, Joshua, Hoering, Antje, Crowley, John, Barlogie, Bart
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3677537/
https://ncbi.nlm.nih.gov/pubmed/22855579
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-0019
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados